Medical Condition News

RSS

Covidien releases results of TurboHawk and SpiderFX combination study on P.A.D.

Covidien, a leading global provider of healthcare products, today released the results of the DEFINITIVE Ca++ study.

24 Jan 2012

High-fiber diet may raise risk of diverticulosis

For more than 40 years, scientists and physicians have thought eating a high-fiber diet lowered a person's risk of diverticulosis, a disease of the large intestine in which pouches develop in the colon wall. A new study of more than 2,000 people reveals the opposite may be true.

24 Jan 2012

Chromosome aberrations happen in pairs when it comes to cancer

A healthy genome is characterized by 23 pairs of chromosomes, and even a small change in this structure - such as an extra copy of a single chromosome - can lead to severe physical impairment. So it's no surprise that when it comes to cancer, chromosomal structure is frequently a contributing factor, says Prof. Ron Shamir of the Blavatnik School of Computer Science at Tel Aviv University.

24 Jan 2012

Study takes a closer look at high fructose corn syrup and table sugar

With growing concern that excessive levels of fructose may pose a great health risk - causing high blood pressure, kidney disease and diabetes - researchers at the University of Colorado School of Medicine, along with their colleagues at the University of Florida, set out to see if two common sweeteners in western diets differ in their effects on the body in the first few hours after ingestion.

24 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

CQA derivatives in mate tea kill human colon cancer cells

Could preventing colon cancer be as simple as developing a taste for yerba mate tea? In a recent University of Illinois study, scientists showed that human colon cancer cells die when they are exposed to the approximate number of bioactive compounds present in one cup of this brew, which has long been consumed in South America for its medicinal properties.

24 Jan 2012

Perrigo files ANDA and confirms Astepro Nasal Spray patent challenge

Perrigo Company announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for azelastine hydrochloride nasal spray (0.15%) and has notified Meda Pharmaceuticals, Inc., the owner of the New Drug Application (NDA) of its filing. The ANDA filing involved contributions from both Perrigo and Impax Laboratories, Inc., who will share costs and benefits of this project.

24 Jan 2012

Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.

24 Jan 2012

Targeting a single protein can help fight both breast cancers and leukemias

Targeting a single protein can help fight both breast cancers and leukemias, according to two reports published online on January 23 in the Journal of Experimental Medicine.

24 Jan 2012

Scientists reveal structure of cellular protein degradation machinery

Defective proteins that are not disposed of by the body can cause diseases such as Alzheimer's or Parkinson's. Scientists at the Max Planck Institute (MPI) of Biochemistry recently succeeded in revealing the structure of the cellular protein degradation machinery (26S proteasome) by combining different methods of structural biology.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Possible link between vascular lesions and Alzheimer's disease

Approximately 20 percent of all stroke survivors will develop cognitive problems later in life, including vascular dementia. Experts with the Methodist Neurological Institute in Houston say recent research showing a possible link between vascular lesions and Alzheimer's disease is yet another reason to be more vigilant in our efforts to prevent a stroke.

24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

PLC Systems initiates enrollment in RenalGuard pivotal trial for CIN

PLC Systems Inc., a company focused on innovative medical device technologies, announced the successful enrollment of the first patient in the CIN-RG trial, the company's pivotal trial to study the efficacy of its RenalGuard Therapy and RenalGuard System in the prevention of Contrast-Induced Nephropathy.

24 Jan 2012

Novel method can rapidly scan and capture 3D maps of muscle structure

Simon Fraser University associate professor James Wakeling is adding to the arsenal of increasingly sophisticated medical imaging tools with a new signal-processing method for viewing muscle activation details that have never been seen before.

23 Jan 2012

UCSF-led study to sequence DNA from 4,000 people with epilepsy

To probe the genetic secrets of one of the most common neurological diseases, more than 4,000 people with various forms of epilepsy will have their DNA decoded over the next five years in a study led by researchers at the University of California, San Francisco (UCSF) and several collaborating institutions.

23 Jan 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

Patient enrollment complete in Enlivex Phase I/II clinical trial for autoimmune diseases

Hadasit Bio-Holdings a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.

23 Jan 2012

The costs of cancer care

But an economic drama that neither [political party] wants to confront is playing itself out in cancer wards and oncologists' offices across the country.

23 Jan 2012

FzioMed's DYNAVISC adhesion barrier gel receives European CE Mark approval

FzioMed, Inc. is pleased to announce that it has received CE Mark approval to market DYNAVISC adhesion barrier gel in Europe for tendon and peripheral nerve surgery.

23 Jan 2012